HK1192323A1 - -微管蛋白作為對呋咱並苯並咪唑類的藥物反應的生物標誌物的用途 - Google Patents
-微管蛋白作為對呋咱並苯並咪唑類的藥物反應的生物標誌物的用途Info
- Publication number
- HK1192323A1 HK1192323A1 HK14105637.2A HK14105637A HK1192323A1 HK 1192323 A1 HK1192323 A1 HK 1192323A1 HK 14105637 A HK14105637 A HK 14105637A HK 1192323 A1 HK1192323 A1 HK 1192323A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- glu
- furazanobenzimidazoles
- tubulin
- biomarker
- drug response
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/44—Multiple drug resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Physiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11151681 | 2011-01-21 | ||
| PCT/EP2012/050814 WO2012098203A1 (en) | 2011-01-21 | 2012-01-19 | Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1192323A1 true HK1192323A1 (zh) | 2014-08-15 |
Family
ID=43928137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK14105637.2A HK1192323A1 (zh) | 2011-01-21 | 2014-06-13 | -微管蛋白作為對呋咱並苯並咪唑類的藥物反應的生物標誌物的用途 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9995754B2 (zh) |
| EP (1) | EP2666014B1 (zh) |
| JP (1) | JP6270481B2 (zh) |
| CN (1) | CN103460042B (zh) |
| AU (1) | AU2012208516B2 (zh) |
| CA (2) | CA3142744A1 (zh) |
| DK (1) | DK2666014T3 (zh) |
| ES (1) | ES2608315T3 (zh) |
| HK (1) | HK1192323A1 (zh) |
| HU (1) | HUE031162T2 (zh) |
| PL (1) | PL2666014T3 (zh) |
| PT (1) | PT2666014T (zh) |
| WO (1) | WO2012098203A1 (zh) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10006078B2 (en) * | 2011-03-29 | 2018-06-26 | Basilea Pharmaceutica Ag | Use of phospho-Akt as a biomarker of drug response |
| WO2017068182A1 (en) | 2015-10-22 | 2017-04-27 | Basilea Pharmaceutica Ag | Use of eb1 as a biomarker of drug response |
| US10170419B2 (en) * | 2016-06-22 | 2019-01-01 | International Business Machines Corporation | Biconvex low resistance metal wire |
| KR102648947B1 (ko) | 2017-04-26 | 2024-03-18 | 바실리어 파마슈티카 인터내셔널 리미티드 | 푸라자노벤즈이미다졸 및 이의 결정 형태의 제조 공정 |
| WO2018210868A1 (en) | 2017-05-16 | 2018-11-22 | Basilea Pharmaceutica International AG | Novel dosage principle for drugs useful for treating neoplastic diseases |
| US11419856B2 (en) | 2017-11-20 | 2022-08-23 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| CN109053584B (zh) * | 2018-09-12 | 2022-03-18 | 南京大学 | 一类1，2-二芳基苯并咪唑衍生物的制备及其应用 |
| WO2022053549A1 (en) | 2020-09-10 | 2022-03-17 | Basilea Pharmaceutica International AG | Use of c-myc as a biomarker of drug response |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1230552B1 (en) | 1999-11-16 | 2006-01-11 | Genentech, Inc. | Elisa for vegf |
| ES2300775T3 (es) * | 2003-05-23 | 2008-06-16 | Basilea Pharmaceutica Ag | Furazanobencimidazoles. |
| ES2481672T3 (es) * | 2003-07-17 | 2014-07-31 | Pacific Edge Limited | Marcadores para la detección del cáncer gástrico |
| WO2005098446A2 (en) * | 2004-03-31 | 2005-10-20 | The Johns Hopkins University | Biomarkers for ovarian cancer |
| US8193238B2 (en) * | 2006-03-08 | 2012-06-05 | University Of Maryland, Baltimore | Inhibition of microtubule protrusion in cancer cells |
| US20110165178A1 (en) * | 2007-01-23 | 2011-07-07 | Centre National De La Recherche Scientifique (Cnrs) | Diagnosis of prostate cancer |
| DK2459553T3 (da) | 2009-07-27 | 2014-11-03 | Basilea Pharmaceutica Ag | Furazanobenzimidazoler som prodrug til behandling af neoplastiske eller autoimmune sygdomme |
-
2012
- 2012-01-19 ES ES12700494.3T patent/ES2608315T3/es active Active
- 2012-01-19 PT PT127004943T patent/PT2666014T/pt unknown
- 2012-01-19 CN CN201280005860.3A patent/CN103460042B/zh active Active
- 2012-01-19 WO PCT/EP2012/050814 patent/WO2012098203A1/en active Application Filing
- 2012-01-19 PL PL12700494T patent/PL2666014T3/pl unknown
- 2012-01-19 JP JP2013549810A patent/JP6270481B2/ja active Active
- 2012-01-19 DK DK12700494.3T patent/DK2666014T3/en active
- 2012-01-19 US US13/980,208 patent/US9995754B2/en active Active
- 2012-01-19 EP EP12700494.3A patent/EP2666014B1/en active Active
- 2012-01-19 AU AU2012208516A patent/AU2012208516B2/en active Active
- 2012-01-19 HU HUE12700494A patent/HUE031162T2/en unknown
- 2012-01-19 CA CA3142744A patent/CA3142744A1/en active Pending
- 2012-01-19 CA CA2822530A patent/CA2822530C/en active Active
-
2014
- 2014-06-13 HK HK14105637.2A patent/HK1192323A1/zh unknown
-
2018
- 2018-05-22 US US15/986,577 patent/US10656162B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2822530C (en) | 2023-02-21 |
| US20180364254A1 (en) | 2018-12-20 |
| CA3142744A1 (en) | 2012-07-26 |
| CN103460042B (zh) | 2015-12-02 |
| ES2608315T3 (es) | 2017-04-07 |
| US9995754B2 (en) | 2018-06-12 |
| US20140024686A1 (en) | 2014-01-23 |
| WO2012098203A1 (en) | 2012-07-26 |
| CA2822530A1 (en) | 2012-07-26 |
| PT2666014T (pt) | 2016-12-22 |
| DK2666014T3 (en) | 2017-01-09 |
| JP2014505876A (ja) | 2014-03-06 |
| CN103460042A (zh) | 2013-12-18 |
| AU2012208516B2 (en) | 2015-11-19 |
| AU2012208516A1 (en) | 2013-06-20 |
| EP2666014B1 (en) | 2016-10-05 |
| JP6270481B2 (ja) | 2018-01-31 |
| US10656162B2 (en) | 2020-05-19 |
| HUE031162T2 (en) | 2017-07-28 |
| NZ611525A (en) | 2015-06-26 |
| EP2666014A1 (en) | 2013-11-27 |
| PL2666014T3 (pl) | 2017-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1244183A1 (zh) | Ivacaftor的氘化衍生物 | |
| EP2750635A4 (en) | REFERENCE TO RELATED APPLICATIONS | |
| GB201104096D0 (en) | Production of graphene | |
| HUE047354T2 (hu) | Ivacaftor deuterizált származékai | |
| HK1191096A1 (zh) | 乙酰化微管蛋白作為對呋咱並苯並咪唑類的藥物反應的生物標誌物的用途 | |
| HK1192323A1 (zh) | -微管蛋白作為對呋咱並苯並咪唑類的藥物反應的生物標誌物的用途 | |
| HK1189056A1 (zh) | 作為藥物對呋咱並苯並咪唑響應的生物標記的用途 | |
| HK1185947A1 (zh) | 作為呋咱並苯並咪唑類藥物應答的生物標記的用途 | |
| ZA201306520B (en) | Use of phospho-akt as a biomarker of drug response | |
| EP2773262A4 (en) | ASSESSMENT OF A CARDIAL STRUCTURE | |
| EP2776586A4 (en) | BIOMARKERS OF REACTION ON PROTEASOMAL INHIBITORS | |
| PL2753330T3 (pl) | Terapeutyczne zastosowania ektoiny | |
| GB2489486B (en) | Improvements relating to construction | |
| EP2683411A4 (en) | METHODS OF USING MICROARN-26A FOR PROMOTING ANGIOGENESIS | |
| HK1203355A1 (zh) | '- '-去鐵硫素類似物的用途 | |
| EP2776043A4 (en) | BIOMARKERS OF REACTION ON PROTEASOMAL INHIBITORS | |
| EP2684869A4 (en) | PREPARATION OF 3-MERCAPOTOPROPIONATES | |
| EP2782902A4 (en) | DERIVATIVES FROM PHENOXYISOBUTTERIC ACID | |
| EP2791349A4 (en) | SYNTHESIS OF N-ACETYL-D-NEURAMIC ACID | |
| EP2702991A4 (en) | COMPOSITION OF ENTACOPONE | |
| HUE050880T2 (hu) | Fotokémiailag hasítható vegyületek alkalmazása | |
| GB201116456D0 (en) | Improvements relating to foorwear | |
| GB201106098D0 (en) | Production of fuels | |
| GB201209895D0 (en) | Use of a composition | |
| ZA201205358B (en) | Use of a salt of bistetrazolylamine |